The global common warts market garnered a market value of US $ 770 Million in 2023 and is expected to accumulate a market value of US$ 1100 Million by registering a CAGR of 3.6% in the forecast period 2023 to 2033. The worldwide common warts market was extremely strong in 2021 and is predicted to exhibit a quick revenue CAGR during the forecast period. Immunosuppression is a substantial risk factor for persistent infections with Human Papilloma Viruses (HPV) and HPV-associated illness, with a frequency of 10% to 20% among school-aged children.
During the COVID pandemic, the number of immunocompromised people grew, leading to market expansion. However, the worldwide common warts market might be limited by high treatment prices and a lack of treatment availability. During the projected period, factors such as the expanding geriatric population are likely to fuel market revenue growth. The growing number of people being diagnosed with warts, owing to developments in diagnostics and HPV infections, is a key driver driving market expansion.
According to the Centers for Disease Control and Prevention, 340,000 to 360,000 people are affected by HPV-related genital warts each year. In the USA, approximately one in every 100 sexually active persons has genital warts at any one time. Moreover, the increasing frequency of warts in the general population is expected to increase the market for common warts. Furthermore, the market is expanding as a result of a rise in scientific trials conducted by various pharmaceutical companies and an increased need for specific therapy to address various issues caused by common warts. These are the variables that are driving the common warts market forward.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 770 Million |
| Anticipated Forecast Value (2033) | US$ 1,100 Million |
| Projected Growth Rate (2023 to 2033) | 3.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for common warts is projected to increase at a CAGR of 3.6% during the forecast period between 2022 and 2032, reaching a total of US$ 1,100 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 2%.
The recurrence rate of genital warts treated with topical podophyllotoxin therapy ranges between 6% and 100%. According to the Centers for Disease Control and Prevention (CDC), anogenital warts often reoccur within three months. Thus, when the recurrence incidence of warts increases, so does the use of goods and therapy, driving the market for common warts.
HPV viruses promote excessive and fast development of keratin, a hard protein found on the skin's top layer. According to the Anal Cancer Foundation, an estimated 14 million people in the USA are infected with HPV each year. According to the Centers for Disease Control and Prevention (CDC), genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the USA each year. As a result, an increase in the prevalence of warts and HPV infections supports the expansion of the common warts market.
The Increasing Prevalence of Common Warts and HPV infections is propelling Market Growth
People with weaker immune systems as a result of organ transplants, major illnesses such as cancer or AIDS, and atopic disorders are more likely to get warts. As a result, an increase in the number of cancer patients raises the prevalence of warts, driving the common warts market.
An increase in the number of HPV infections increases the danger of warts and, as a result, the market. According to the Anal Cancer Foundation, an estimated 14 million people in the USA are infected with HPV each year. According to the Centers for Disease Control and Prevention, genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the USA each year, and they normally appear 2 to 3 months after HPV infection.
There are several treatments available for warts, but recurrences are common. A large majority of instances of genital warts do not respond to therapy and frequently reoccur, especially when infections from HPV have a protracted incubation period. As a result, an increase in the recurrence rate of common warts increases the need for products and therapy. This, in turn, is projected to fuel the market for common warts.
Principal Consultant
The Common Warts Market is being Hampered by a Low Diagnostic Rate due to a Lack of Awareness
The expansion of the worldwide common warts market is anticipated to be impeded by a lack of knowledge of the diagnosis, which results in fewer reported instances and, as a result, less relevance for treatment choices. Although the frequency of warts is increased, the diagnostic rate in patients is low.
For example, according to the 2018 Health Protection Report, the prevalence of genital warts diagnosis among girls aged 15 to 17 in England accessing sexual health services reduced by 92% compared to 2014.
Government Support to Raise Awareness about Sexually Transmitted Diseases Widening Profit Margins
Over the projection period, Asia Pacific is predicted to have high revenue CAGR. There is a significant growth in the elderly population in nations such as China, India, and others.
The region's development rate will be enhanced due to the presence of generic producers and the expansion of healthcare facilities. These important drivers are projected to fuel market revenue growth throughout the forecast period.
Government support to raise awareness about sexually transmitted diseases, an increase in demand for advanced therapeutics, an increase in the prevalence of HPV infections, a rising economy, and a shift in sexual lifestyles in the area are key drivers of the Asia Pacific common warts market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023 to 2033.
Increase in Pharmaceutical Firms' Research and Development Efforts to Accelerate Market Growth
The development of the North American market is attributable to an increase in pharmaceutical firms' Research and Development efforts, a high rate of treatment acceptance in healthcare facilities, and a rise in knowledge about the impacts of common warts. North America is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Because of Its Low Cost, Salicylic Acid Improves Clinical Outcomes
There is a growing desire for common warts therapy that leaves no scars and gives lifetime protection against HPV. As a result, businesses in the common warts market are focusing more on tissue keratolysis in order to improve patient results.
Tissue keratolysis, which uses salicylic acid, is popular in over-the-counter (OTC) drugs. This is clear since salicylic acid, a chemical destruction therapy option, is predicted to increase at an exponential rate in the common warts market throughout the projection period.
Key players in the common warts market are Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassiopeia Pharmaceuticals, Innovax, and Torii Pharmaceutical Co. Ltd.
Recent Developments
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 770 Million |
| Market Value in 2033 | US$ 1,100 Million |
| Growth Rate | CAGR of 3.6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global common warts market to expand at a 3.6% value CAGR by 2033
The global common warts market is estimated at a market value of US$ 770 Million
The global market for common warts treatment is expected to garner a market value of US$ 1100 Million
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023 to 2033.
Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd., are some prominent Common Warts manufacturers
North America is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023 to 2033.
The Salicylic Acid segment is expected to hold the largest market share for common warts in the forecast period 2023 to 2033.
1. Executive Summary | Common Warts Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis Procedure 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis Procedure, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis Procedure, 2023 to 2033 5.3.1. Biopsy 5.3.2. Excision 5.4. Y-o-Y Growth Trend Analysis By Diagnosis Procedure, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Diagnosis Procedure, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 6.3.1. Imiquimod 6.3.2. Silver Nitrate 6.3.3. Glutaraldehyde 6.3.4. Salicylic Acid 6.3.5. Formaldehyde 6.3.6. Aminolevulinic Acid 6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Medication Class 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Medication Class, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Medication Class, 2023 to 2033 7.3.1. Topical Retinoids 7.3.2. Oral Retinoids 7.4. Y-o-Y Growth Trend Analysis By Medication Class, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Medication Class, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. United States of America 9.2.1.2. Canada 9.2.2. By Diagnosis Procedure 9.2.3. By Drug Type 9.2.4. By Medication Class 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Diagnosis Procedure 9.3.3. By Drug Type 9.3.4. By Medication Class 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Diagnosis Procedure 10.2.3. By Drug Type 10.2.4. By Medication Class 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Diagnosis Procedure 10.3.3. By Drug Type 10.3.4. By Medication Class 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Diagnosis Procedure 11.2.3. By Drug Type 11.2.4. By Medication Class 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Diagnosis Procedure 11.3.3. By Drug Type 11.3.4. By Medication Class 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Diagnosis Procedure 12.2.3. By Drug Type 12.2.4. By Medication Class 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Diagnosis Procedure 12.3.3. By Drug Type 12.3.4. By Medication Class 12.4. Key Takeaways 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Diagnosis Procedure 13.2.3. By Drug Type 13.2.4. By Medication Class 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Diagnosis Procedure 13.3.3. By Drug Type 13.3.4. By Medication Class 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. United States of America 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Diagnosis Procedure 14.1.2.2. By Drug Type 14.1.2.3. By Medication Class 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Diagnosis Procedure 14.2.2.2. By Drug Type 14.2.2.3. By Medication Class 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Diagnosis Procedure 14.3.2.2. By Drug Type 14.3.2.3. By Medication Class 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Diagnosis Procedure 14.4.2.2. By Drug Type 14.4.2.3. By Medication Class 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Diagnosis Procedure 14.5.2.2. By Drug Type 14.5.2.3. By Medication Class 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Diagnosis Procedure 14.6.2.2. By Drug Type 14.6.2.3. By Medication Class 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Diagnosis Procedure 14.7.2.2. By Drug Type 14.7.2.3. By Medication Class 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Diagnosis Procedure 14.8.2.2. By Drug Type 14.8.2.3. By Medication Class 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Diagnosis Procedure 14.9.2.2. By Drug Type 14.9.2.3. By Medication Class 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Diagnosis Procedure 14.10.2.2. By Drug Type 14.10.2.3. By Medication Class 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Diagnosis Procedure 14.11.2.2. By Drug Type 14.11.2.3. By Medication Class 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Diagnosis Procedure 14.12.2.2. By Drug Type 14.12.2.3. By Medication Class 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Diagnosis Procedure 14.13.2.2. By Drug Type 14.13.2.3. By Medication Class 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Diagnosis Procedure 14.14.2.2. By Drug Type 14.14.2.3. By Medication Class 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Diagnosis Procedure 14.15.2.2. By Drug Type 14.15.2.3. By Medication Class 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Diagnosis Procedure 14.16.2.2. By Drug Type 14.16.2.3. By Medication Class 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Diagnosis Procedure 14.17.2.2. By Drug Type 14.17.2.3. By Medication Class 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Diagnosis Procedure 14.18.2.2. By Drug Type 14.18.2.3. By Medication Class 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Diagnosis Procedure 14.19.2.2. By Drug Type 14.19.2.3. By Medication Class 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Diagnosis Procedure 14.20.2.2. By Drug Type 14.20.2.3. By Medication Class 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Diagnosis Procedure 15.3.3. By Drug Type 15.3.4. By Medication Class 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Nielsen BioSciences 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Verrica Pharmaceutical 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Aclaris Therapeutics, Inc. 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. KinoPharma, Inc. 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. pHion Therapeutics 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Orgenesis 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Novan 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Cassopeia Pharmaceuticals 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Innovax 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Torii Pharmaceutical Co. Ltd. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Common Warts Market
